Norton Rose Fulbright Adds Chicago M&A Partner Amid Life Sciences Deal Surge
Event summary
- Norton Rose Fulbright hires John Boelter as Chicago-based M&A partner, strengthening its life sciences and pharmaceuticals practice.
- Boelter joins from Mayer Brown with expertise in high-profile domestic and cross-border transactions.
- He is the twelfth US lateral partner hire for Norton Rose Fulbright in 2026 and sixth transaction-focused addition to the Chicago office in 18 months.
- The firm's Global M&A Trends report predicts a 52% increase in global dealmaking activity in 2026, with the US as a key market.
The big picture
Norton Rose Fulbright's strategic expansion in Chicago reflects broader industry trends of increased M&A activity, particularly in life sciences and technology sectors. The firm is positioning itself as a global leader in complex transactions by investing heavily in specialized talent and expanding its footprint in key markets. With over 3,000 lawyers worldwide, the addition of Boelter underscores the firm's commitment to strengthening its corporate practice amid renewed confidence in dealmaking.
What we're watching
- Deal Pipeline Growth
- How Norton Rose Fulbright's expanded Chicago team will impact its ability to capture market share in life sciences M&A.
- Regulatory Complexity
- Whether the firm can sustain its growth by effectively navigating highly regulated sectors like pharmaceuticals and financial services.
- Talent Retention
- The pace at which Norton Rose Fulbright can attract and integrate top-tier lateral partners to maintain its competitive edge.
Related topics